Idera Pharmaceuticals, Inc. has entered into a Materials Cooperative Research and Development Agreement (M-CRADA) with the National Cancer Institute (NCI) to evaluate its toll-like receptor antagonists as a potential treatment of certain genetically defined B-cell lymphomas.   “We are pleased to have entered into this agreement, and we look forward to communicating further on it as the work underway proceeds,” said Sudhir Agrawal, D. Phil., chief executive officer of Idera Pharmaceut...